312 related articles for article (PubMed ID: 35013191)
1. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.
Koerber N; Priller A; Yazici S; Bauer T; Cheng CC; Mijočević H; Wintersteller H; Jeske S; Vogel E; Feuerherd M; Tinnefeld K; Winter C; Ruland J; Gerhard M; Haller B; Christa C; Zelger O; Roggendorf H; Halle M; Erber J; Lingor P; Keppler O; Zehn D; Protzer U; Knolle PA
Nat Commun; 2022 Jan; 13(1):153. PubMed ID: 35013191
[TBL] [Abstract][Full Text] [Related]
2. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
[TBL] [Abstract][Full Text] [Related]
3. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
[TBL] [Abstract][Full Text] [Related]
4. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
5. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
6. Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4
Meyer-Arndt L; Schwarz T; Loyal L; Henze L; Kruse B; Dingeldey M; Gürcan K; Uyar-Aydin Z; Müller MA; Drosten C; Paul F; Sander LE; Demuth I; Lauster R; Giesecke-Thiel C; Braun J; Corman VM; Thiel A
J Immunol; 2022 Mar; 208(5):1001-1005. PubMed ID: 35121642
[TBL] [Abstract][Full Text] [Related]
7. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.
Yang Y; Yang M; Peng Y; Liang Y; Wei J; Xing L; Guo L; Li X; Li J; Wang J; Li M; Xu Z; Zhang M; Wang F; Shi Y; Yuan J; Liu Y
Nat Microbiol; 2022 Mar; 7(3):423-433. PubMed ID: 35132197
[TBL] [Abstract][Full Text] [Related]
9. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
Wratil PR; Stern M; Priller A; Willmann A; Almanzar G; Vogel E; Feuerherd M; Cheng CC; Yazici S; Christa C; Jeske S; Lupoli G; Vogt T; Albanese M; Mejías-Pérez E; Bauernfried S; Graf N; Mijocevic H; Vu M; Tinnefeld K; Wettengel J; Hoffmann D; Muenchhoff M; Daechert C; Mairhofer H; Krebs S; Fingerle V; Graf A; Steininger P; Blum H; Hornung V; Liebl B; Überla K; Prelog M; Knolle P; Keppler OT; Protzer U
Nat Med; 2022 Mar; 28(3):496-503. PubMed ID: 35090165
[TBL] [Abstract][Full Text] [Related]
10. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
11. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.
Cohen H; Rotem S; Elia U; Bilinsky G; Levy I; Chitlaru T; Bar-Haim E
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215940
[TBL] [Abstract][Full Text] [Related]
12. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination.
Almendro-Vázquez P; Laguna-Goya R; Ruiz-Ruigomez M; Utrero-Rico A; Lalueza A; Maestro de la Calle G; Delgado P; Perez-Ordoño L; Muro E; Vila J; Zamarron I; Moreno-Batanero M; Chivite-Lacaba M; Gil-Etayo FJ; Martín-Higuera C; Meléndez-Carmona MÁ; Lumbreras C; Arellano I; Alarcon B; Allende LM; Aguado JM; Paz-Artal E
PLoS Pathog; 2021 Dec; 17(12):e1010211. PubMed ID: 34962970
[TBL] [Abstract][Full Text] [Related]
14. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
15. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
[No Abstract] [Full Text] [Related]
16. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
17. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
18. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
[TBL] [Abstract][Full Text] [Related]
19. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Sahin U; Muik A; Vogler I; Derhovanessian E; Kranz LM; Vormehr M; Quandt J; Bidmon N; Ulges A; Baum A; Pascal KE; Maurus D; Brachtendorf S; Lörks V; Sikorski J; Koch P; Hilker R; Becker D; Eller AK; Grützner J; Tonigold M; Boesler C; Rosenbaum C; Heesen L; Kühnle MC; Poran A; Dong JZ; Luxemburger U; Kemmer-Brück A; Langer D; Bexon M; Bolte S; Palanche T; Schultz A; Baumann S; Mahiny AJ; Boros G; Reinholz J; Szabó GT; Karikó K; Shi PY; Fontes-Garfias C; Perez JL; Cutler M; Cooper D; Kyratsous CA; Dormitzer PR; Jansen KU; Türeci Ö
Nature; 2021 Jul; 595(7868):572-577. PubMed ID: 34044428
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
